You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華森製藥(002907.SZ):獲得奧美拉唑碳酸氫鈉膠囊藥品補充申請批准通知書暨成為藥品上市許可持有人
格隆匯 10-20 19:26

格隆匯10月20日丨華森製藥(002907.SZ)公佈,公司於2018628日與北京百奧藥業有限責任公司(“北京百奧”)簽訂了關於奧美拉唑碳酸氫鈉膠囊(規格:20mg1100mg)的《技術開發及轉讓合同》,百奧藥業於20215月取得了國家藥品監督管理局(“國家藥監局”)核准簽發的《藥品註冊證書》(證書編號:2021S00512)(第3類)。具體內容詳見公司分別於2018630日和2021526日披露的《關於簽訂<技術開發及轉讓合同>的公吿》(公吿編號:2018-032)和《關於合作方取得奧美拉唑碳酸氫鈉膠囊藥品註冊證書的公吿》(公吿編號:2021-032)。公司隨即開展該產品的上市許可持有人變更工作,持有人變更完成後該產品即進行上市銷售。

公司近日收到國家藥品監督管理局(“國家藥監局”)核准簽發的關於奧美拉唑碳酸氫鈉膠囊的《藥品補充申請批准通知書》,標誌着產品已完成藥品上市許可持有人變更工作,公司已成為藥品上市許可持有人,公司將儘快開展市場營銷工作

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account